Track market-moving stories before they get noisy

As the old saying goes, "If something sounds too good to be true, it probably is."

That clichéd wisdom presents something of a problem for any investor eyeing a new stake in pharmaceutical outfit Pfizer (PFE -0.72%) while its stock is priced at less than 10 times this year's expected per-share profit of $2.98, with a forward-looking dividend yield that's unusually high at just over 6%.

What's the market seeing? Maybe it's what the market's not seeing. To this end, if you're thinking about diving in, here are the top three things you need to know about Pfizer today.

1. The real revenue turning point is 2030 All stock prices reflect that company's plausible future more so than its past, or even its present. The challenge for investors interested in Pfizer at this time is how far into the future they need to look.

While its acquisitions and in-house research and development work on this front are certainly promising, the company's goal of having eight new blockbuster oncology drugs on the market -- and doubling its total number of cancer patients it's currently serving as a result -- won't even begin to start happening until after 2028, and not in earnest until 2030.

image source: Getty Images.

Meanwhile, its top-selling drugs like cancer-fighting Ibrance, pneumonia vaccine Prevnar, and blood-thinner Eliquis (which accounts for about 15% of Pfizer's total revenue) will lose their patent protection. In other words, it could be a tough few years between now and 2030,

2. Its cost-cutting goals aggressive At the same time, the drugmaker is setting up new profit centers to offset the eventual wind-down of others, and it's also cutting costs. Specifically, between this year and 2029, Pfizer expects to find $9.7 billion worth of operational savings. Most will come from cost realignments, but some will be the result of manufacturing optimization.

For perspective on that number, the company's on pace to do on the order of $62 billion worth of business this year. That's also more than all of last year's net income.

3. The high yield and low valuation make it worth the risk Finally, although the stock's dirt cheap valuation and oddly high dividend yield suggest most investors doubt Pfizer will be able to achieve its goals anytime soon (and with a consensus 12-month price target of only $28.28 per share, most analysts seem to agree), this is a scenario where investors should think longer term, recognizing that Pfizer's forced overhaul isn't anything new or unusual for it or any other names in the pharmaceutical industry. It should be a far more promising company five years from now.

Premium Feature

Moneyball Superscore

64/100

Today's Change

(

-0.72

%) $

-0.21

Current Price

$

28.81

Also, remember that most stocks tend to move in anticipation of turnarounds, because they actually take hold. In this vein, Pfizer's got a great deal of drug-development progress news already lined up for the next five years, which will give investors plenty of bullish milestones to latch onto. Just make sure you're ready for a bumpy ride during this stretch.

A month has gone by since the last earnings report for Pfizer (PFE - Free Report) . Shares have added about 12.4% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Pfizer due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Pfizer Inc. before we dive into how investors and analysts have reacted as of late.

Q2 Earnings & Sales Beat EstimatesPfizer reported second-quarter 2026 adjusted earnings per share of 77 cents, which beat the Zacks Consensus Estimate of 68 cents per share. Earnings were flat year over year.

Revenues came in at $15.03 billion, up 3% from the year-ago quarter on a reported basis and 1% on an operational basis. Total revenues beat the Zacks Consensus Estimate of $14.45 billion. Growth in Eliquis, Padcev, the Vyndaqel family and Lorbrena offset steep declines in COVID-19 products.

 International revenues rose 3% on an operational basis to $6.18 billion. U.S. revenues were flat at $8.86 billion.

Excluding BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer’s newly launched and acquired products delivered $3.2 billion in revenues and grew 18% operationally in the quarter. Excluding one-time items recorded in the second quarter of 2025, primarily related to the legacy Seagen in-line portfolio, this operational growth would have been 27%.

Adjusted selling, informational and administrative (SI&A) expenses declined 3% (operationally) in the quarter to $3.34 billion due to lower spending in corporate enabling functions. Adjusted R&D expenses rose 12% to $2.73 billion due to higher spending on oncology and obesity pipeline.

Segment DiscussionPfizer reports its revenues under three broad sub-segments of its Biopharma operating segment — Primary Care, Specialty Care and Oncology. In first-quarter 2026, Pfizer created a new Hospital and Biosimilars Division within its Biopharma segment, moving certain off-patent brands, generic sterile injectables and biosimilars out of Specialty Care and Oncology.

Primary Care sales declined 2% on an operational basis to $5.5 billion. Oncology revenues rose 2% to $4.17 billion, while Specialty Care sales increased 7% to $3.35 billion. Hospital and Biosimilars revenues declined 2% to $1.64 billion.

Primary CareIn Primary Care, alliance revenues and direct sales from Eliquis increased 19% to $2.43 billion as higher demand trends globally were partially offset by price and generic erosion in some ex-U.S. markets. Eliquis sales beat the Zacks Consensus Estimate of $1.98 billion.

Global Prevnar family revenues declined 4% to $1.34 billion and missed the consensus estimate of $1.39 billion. U.S. sales fell 13%, more than offsetting a 10% increase in the international market. U.S. sales declined due to lower vaccination rates in the pediatric and adult indications. International sales rose due to continued increases in demand in both the adult and pediatric indications.

Direct sales and alliance revenues from partner BioNTech for Comirnaty were $261.0 million in the quarter, down 34% year over year, missing the consensus estimate of $278 million. The decrease reflected a smaller favorable adjustment to the returns provision and lower U.S. utilization following narrower vaccination recommendations.

Paxlovid revenues plunged 95% to $21 million due to lower COVID-19 infections and reduced government purchases in some international markets. Sales fell well short of the consensus estimate of $119 million.

Nurtec ODT/Vydura contributed $421.0 million in the quarter, up 17% year over year, driven by strong demand and prescription growth.

Among the new products, Pfizer’s RSV vaccine, Abrysvo, recorded sales of $208 million, up 43% on an operational basis, driven by launch uptake and favorable timing of deliveries in some international markets and favorable buying patterns in the United States.

OncologyIn Oncology, Ibrance revenues were flat at $1.06 billion, exceeding the Zacks Consensus Estimate of $1.05 billion.

Padcev sales climbed 23% to $667 million and surpassed the consensus estimate of $661 million. Padcev benefited from strong demand trends mainly due to market share gains in first-line metastatic urothelial cancer and launch momentum from the new muscle-invasive bladder cancer indication.

Xtandi alliance revenues declined 6% to $534 million. Lorbrena revenues rose 37% to $354 million, driven by market share gains in the first-line ALK-positive metastatic NSCLC treatment setting in the United States, China, and some other international countries. Adcetris sales fell 23% to $196 million. Inlyta revenues decreased 12% to $218 million. Braftovi/Mektovi revenues rose 23% to $223 million.

New drug, Elrexfio, generated sales of $89 million in the quarter, up 5% year over year.

Pfizer's Specialty Care and Hospital SalesVyndaqel family revenues increased 8% to $1.76 billion, slightly exceeding the Zacks Consensus Estimate of $1.75 billion. The Vyndaqel family includes global revenues from Vyndaqel as well as revenues from Vyndamax in the United States and Vynmac in Japan. Growth reflected continued patient diagnosis and improved access in international markets, along with U.S. market expansion, which partially offset the impact of price erosion as a result of new payer contracts in the United States.

Xeljanz sales declined 23% to $251 million, while Enbrel revenues fell 10% to $142 million. Cibinqo sales rose 34% to $94 million.

Within Hospital and Biosimilars, oncology biosimilar sales increased 1% to $359 million, and Inflectra revenues rose 23% to $171 million.

2026 GuidancePfizer raised the lower end of its 2026 revenue guidance, backed by continued strong performance of its new and acquired products. The company now expects revenues between $60.5 billion and $62.5 billion, compared with the previous range of $59.5 billion to $62.5 billion. The range indicates a decline from 2025 revenues of $62.6 billion due to lower revenues from COVID products and loss of revenues from the upcoming patent cliff.

The revised outlook reflects approximately $1.5 billion of better-than-expected non-COVID product performance, partly offset by a $1 billion reduction in expected COVID-19 product revenues. Pfizer now expects around $4 billion from COVID-19 products in 2026, lower than the prior expectation of around $5 billion.

Paxlovid demand is expected to be limited due to low COVID infection levels. Meanwhile, most sales of Comirnaty are expected later in the year, in line with the seasonal vaccination period.

The adjusted earnings guidance was reaffirmed at $2.80-$3.00 per share. However, the guidance now absorbs a 10 cents per share charge related to its licensing deal with Chinese biotech Innovent Biologics that will be recorded in the third quarter of 2026.

Adjusted gross margin is expected to be in the mid-70s range, similar to the past several years. Adjusted R&D expenses are expected to be in the range of $10.5 billion to $11.5 billion in 2026, while adjusted SI&A spending is targeted between $12.5 billion and $13.5 billion. The adjusted effective tax rate is expected to be approximately 15% in 2026.

Pfizer also said it expects additional cost savings of $2.5 billion, which it expects to realize from 2027 through 2029.

Pfizer remains on track to achieve approximately $5.7 billion in net savings from its ongoing cost realignment program by the end of 2026 and has expanded the initiative with an additional $1 billion in expected SG&A savings through 2029, bringing total savings from the program to about $6.7 billion through 2029. Separately, the company has expanded its multi-year manufacturing optimization program, which is now expected to generate approximately $3 billion in cumulative cost-of-goods savings by 2029. Overall, Pfizer expects approximately $9.7 billion in total net savings from its productivity enhancement initiative through 2029.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.

The consensus estimate has shifted -8.39% due to these changes.

VGM ScoresAt this time, Pfizer has a average Growth Score of C, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Pfizer has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerPfizer is part of the Zacks Large Cap Pharmaceuticals industry. Over the past month, AbbVie (ABBV - Free Report) , a stock from the same industry, has gained 6.3%. The company reported its results for the quarter ended June 2026 more than a month ago.

AbbVie reported revenues of $16.99 billion in the last reported quarter, representing a year-over-year change of +10.2%. EPS of $3.65 for the same period compares with $2.97 a year ago.

For the current quarter, AbbVie is expected to post earnings of $3.86 per share, indicating a change of +107.5% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.5% over the last 30 days.

AbbVie has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.

Archer Investment Corp bought a new position in shares of Pfizer Inc. (NYSE:PFE – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund bought 73,546 shares of the biopharmaceutical company’s stock, valued at approximately $1,771,000.

Other institutional investors have also recently made changes to their positions in the company. Handelsbanken Fonder AB lifted its stake in Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after buying an additional 232,528 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after purchasing an additional 745,213 shares during the period. Leuthold Group LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $4,887,000. North Dakota State Investment Board acquired a new position in shares of Pfizer during the fourth quarter worth approximately $5,348,000. Finally, Park National Corp OH boosted its position in shares of Pfizer by 332.1% during the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after buying an additional 186,053 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.2% NYSE:PFE opened at $27.95 on Friday. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75. The company has a market cap of $159.31 billion, a PE ratio of 36.78 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a 50-day moving average of $25.55 and a 200-day moving average of $26.30.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year. Pfizer Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer’s dividend payout ratio is currently 226.32%.

Analyst Upgrades and Downgrades Several brokerages have weighed in on PFE. UBS Group reaffirmed a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Wolfe Research reissued an “underperform” rating and set a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. JPMorgan Chase & Co. reduced their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. BMO Capital Markets decreased their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, Weiss Ratings cut shares of Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.28.

View Our Latest Research Report on PFE

Pfizer News Roundup Here are the key news stories impacting Pfizer this week:

Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high. About Pfizer (Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

See Also Five stocks we like better than Pfizer 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop? Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Edmond DE Rothschild Holding S.A. reduced its position in Pfizer Inc. (NYSE:PFE – Free Report) by 8.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,455,651 shares of the biopharmaceutical company’s stock after selling 128,428 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Pfizer were worth $35,052,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vermillion Wealth Management Inc. lifted its stake in shares of Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 382 shares during the period. Eagle Capital Management LLC increased its position in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares during the period. Delta Financial Advisors LLC increased its position in Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after purchasing an additional 398 shares during the period. Pines Wealth Management LLC raised its holdings in Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 400 shares during the last quarter. Finally, Mount Vernon Associates Inc. MD raised its holdings in Pfizer by 1.0% during the 1st quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock worth $1,177,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In Several brokerages have recently issued reports on PFE. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and reduced their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Guggenheim cut their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. JPMorgan Chase & Co. lowered their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Finally, Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.28.

Check Out Our Latest Stock Report on PFE Pfizer Price Performance Pfizer stock opened at $28.00 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $159.59 billion, a P/E ratio of 36.84 and a beta of 0.34. The business has a 50-day moving average of $25.30 and a 200-day moving average of $26.25. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the company posted $0.78 EPS. Pfizer’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.1%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Trending Headlines about Pfizer Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims About Pfizer (Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Read More Five stocks we like better than Pfizer 2 Biotech Stocks Shaping Up for Major Breakouts 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Pfizer plans more than 20 obesity studies in 2026, including 10 phase III berobenatide trials.Berobenatide could offer monthly maintenance dosing after an initial weekly injection.Pfizer targets its first potential berobenatide approval in 2028, but faces high execution risk. The global obesity market is emerging as one of the largest growth opportunities in pharmaceuticals. The market is projected to grow dramatically, reaching nearly $114 billion by 2030, according to Goldman Sachs estimates. At present, Eli Lilly’s (LLY - Free Report) Zepbound and Novo Nordisk’s (NVO - Free Report) Wegovy are the most popular GLP-1 drugs used to treat obesity.

To take a share of this market, Pfizer (PFE - Free Report) has made a significant strategic move to participate through its 2025 acquisition of Metsera and development of a broad obesity pipeline. Pfizer’s obesity portfolio includes injectables with the potential for monthly or longer dosing, once-daily orals and other novel combinations

The most important asset added from the Metsera deal is berobenatide (MET-097i), a long-acting GLP-1 receptor agonist that is in phase III development for chronic weight management.

While Zepbound and Wegovy are weekly injections, berobenatide starts off as a weekly injection and then switches to a monthly injection. Berobenatide is designed for monthly maintenance dosing.

Data from phase IIb VESPER studies on berobenatide showed that the candidate delivers meaningful weight loss while maintaining a favorable tolerability profile following the transition from weekly to monthly dosing.

Pfizer plans an extensive phase III program for berobenatide in 2026. Pfizer plans to start more than 20 obesity studies in 2026, including 10 phase III studies for berobenatide for obesity and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea. Three phase III studies on berobenatide have already begun. Pfizer plans to soon start a phase III study evaluating participants switching from approved weekly therapies to monthly berobenatide.

Pfizer is targeting the first of a series of potential approvals for berobenatide in 2028. Pfizer is also evaluating berobenatide in combination with an ultra-long-acting amylin analog, PF'3945, as a monthly medicine in phase II studies with additional data expected later this year.

Can Pfizer Carve Out a Share in the Obesity Market?Pfizer is a late entrant in the obesity market, which is heavily dominated by Lilly and Novo Nordisk. LLY and NVO already enjoy enormous commercial scale and brand recognition in the obesity space.

Moreover, to maintain their prowess in the lucrative obesity market, both Novo Nordisk and Lilly are developing several next-generation, more powerful and more convenient GLP-1-based treatments, including oral options and multi-acting candidates. Both Lilly and Novo Nordisk have also launched oral GLP-1 pills for obesity called Foundayo and Wegovy pill, respectively.

The obesity pipeline is rapidly evolving beyond traditional GLP-1 therapies. Lilly's next-generation candidate, retatrutide, which targets GLP-1, GIP and glucagon receptors simultaneously, has demonstrated profound levels of weight loss and improvements in A1C, cardiovascular risk factors, osteoarthritis pain and sleep apnea, across its TRIUMPH program. Lilly plans to submit the treatment to the FDA in the first quarter of 2027.

Pfizer currently trails Lilly and Novo Nordisk by several years in the obesity space. However, the obesity market is huge and can support multiple players, and even a mid-single-digit market share could translate into billions of dollars in annual revenues.

If Pfizer’s berobenatide succeeds and monthly dosing or better tolerability differentiates it from Zepbound/Wegovy, or if its next-generation oral programs prove competitive, it can take a slice of the obesity space in the long term.

Overall, Pfizer’s obesity opportunity is high potential but has high execution risk as well.

Competition Heating Up in the Obesity SpaceWhile Lilly and Novo Nordisk currently dominate this space, smaller biotechs like Structure Therapeutics and Viking Therapeutics are also developing oral GLP-1 drugs for treating obesity.

Amgen is also developing MariTide, a GIPR/GLP-1 receptor, with a monthly and maybe less frequent dosing.

Others, such as Roche, AstraZeneca (AZN - Free Report) and AbbVie, have strengthened their obesity pipelines through licensing deals and acquisitions involving smaller biotechs. AbbVie entered the obesity field by licensing GUB014295 (now ABBV-295), a long-acting amylin analog, from Gubra in 2025. Roche strengthened its obesity presence through the acquisition of Carmot Therapeutics and its obesity assets, such as enicepatide (previously CT-388), as well as the exclusive collaboration with Zealand Pharma, which added petrelintide, a long-acting amylin analog.

AstraZeneca’s most important obesity candidate is oral GLP-1 receptor agonist elecoglipron, which it licensed from Eccogene in 2023 and is now in phase III.

PFE’s Price Performance, Valuation and Estimates         Pfizer stock has risen 9.5% so far this year compared with an 11.9% growth of the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its five-year mean. Going by the price/earnings ratio, Pfizer’s shares currently trade at 9.24 forward earnings, significantly lower than 18.51 for the industry as well as the stock’s five-year mean of 9.25.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 earnings per share has risen from $2.96 to $2.98, while that for 2027 has increased from $2.85 to $2.93 over the past 30 days.

Image Source: Zacks Investment Research

Pfizer has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Valneva SE (NASDAQ:VALN) stock is surging on Friday after the company and its partner Pfizer Inc. (NYSE:PFE) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, their Lyme disease vaccine candidate.

The EMA will now commence its assessment of the application.

Clinical Trial ResultsThe application for PF-07307405 is supported by encouraging efficacy data from the Phase 3 VALOR clinical trial.

The trial evaluated the vaccine candidate’s ability to prevent Lyme disease in individuals aged five and older. The results demonstrated an efficacy of over 70%.

Furthermore, the vaccine was well-tolerated among trial participants, with no safety concerns reported.

Read Next

In March, the companies released topline results from the Phase 3 VALOR clinical trial for its Lyme disease vaccine candidate, which did not meet the primary endpoint criteria.

The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis.

Collaborative EffortPF-07307405 was developed through a collaboration between Pfizer and Valneva. The vaccine candidate has undergone rigorous evaluation for its efficacy, safety, tolerability, immunogenicity, and manufacturing lot consistency.

The two companies entered into a collaboration and license agreement in April 2020. Under this agreement, they are co-developing PF-07307405, and Pfizer holds the exclusive rights to manufacture and commercialize the vaccine, pending regulatory approval.

VALN Stock Price Activity: Valneva shares were up 24.96% at $7.06 at the time of publication on Friday,
according to Benzinga Pro data.

Photo: Shutterstock

Read Next

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Dividend cuts don't typically happen without warning. Investors can see a business that's in trouble. Perhaps it's in the midst of a turnaround, it's restructuring, or its profits are simply declining, and the dividend may no longer be sustainable. These are all things to watch out for and consider before investing in a stock for its dividend.

Pfizer (PFE +0.87%) is a top healthcare stock, which investors have relied on for years for its growth and reliable payouts. But recently, it has had trouble attracting many investors due to question marks around its growth prospects and its poor financials. This year, its earnings are down big. Does that mean a dividend cut could happen soon?

Image source: Getty Images.

Is Pfizer's dividend still sustainable? Pfizer has been struggling to generate much growth, meanwhile, its expenses have been on the rise as it restructures its business and incorporates recent acquisitions into the fold. In its most recent quarter, which ended on June 30, it incurred a net loss of $248 million, largely due to $3.8 billion worth of impairment charges related to in-process research and development assets.

On a year-to-date basis, the company's net income totaled $2.4 billion, which was down 58% from the $5.9 billion it reported a year ago. Clearly, a big part of the reason for the decline relates to the recent impairment. The good news for income investors: it's a non-cash charge.

What may be more important is to focus on free cash flow, which tells investors how much cash the business has available to fund its payout. The number represents how much cash flow is left after deducting capital expenditures, which are necessary for the company's growth.

Cash can fluctuate significantly depending on when a company pays bills and collects revenue, which is why it's helpful to look beyond just a single period. Over the past four quarters, Pfizer's free cash has totaled $11 billion, which is more than the roughly $9.8 billion it has paid in dividends during that stretch. That's a positive sign that the dividend may still be safe.

Today's Change

(

0.87

%) $

0.23

Current Price

$

26.99

Pfizer has a lot of upside, but it does come with risk Year to date, Pfizer's stock has risen by 9%, but over the past five years, it's down a massive 44%. If it can show that its acquisitions are paying off and get back to growing, as it plans to, then there may be room for the stock to rise significantly higher. But there are no guarantees. The same goes for its dividend, which yields 6.4%. It appears safe for now, but if the company has to conserve cash to invest it into its future growth, there is the possibility that a cut to the payout may happen.

Pfizer could be a good stock to buy for the long haul, but there are definitely safer options out there for income investors.

The past few years have been rough on Pfizer (PFE +2.14%). The company has generally posted subpar financial results due to weakness within its coronavirus franchise, which once helped it become the first biopharmaceutical company to achieve $100 billion in annual sales. The drugmaker is looking to turn things around by developing potential blockbuster products, and one of its most promising candidates is berobenatide, an investigational weight loss therapy. The anti-obesity market is growing rapidly and could be worth $190 billion by 2035, compared to just $79 billion last year, according to some estimates. Could Pfizer's berobenatide help the company capitalize on this large opportunity?

Image source: The Motley Fool.

Challenging the giants Pfizer will have to compete against the leaders in the weight-loss market, Eli Lilly, whose Zepbound is the best-selling drug in this niche, and Novo Nordisk, a pioneer in the market and the company behind Wegovy, perhaps the best-known brand in the field. How does berobenatide compare to Wegovy and Zepbound? It's hard to say without head-to-head clinical trials, but the data we do have so far suggest that Pfizer's candidate could be highly competitive.

In a phase 2b study, berobenatide achieved a weight loss of almost 16% (non-placebo-adjusted) in 32 weeks, with no plateau observed. Those are strong results, considering that Zepbound posted a weight loss of 20.2%, versus Wegovy's 13.7%, in a 72-week head-to-head study. If berobenatide can extend its results in phase 3 studies, we could be looking at the next billion-dollar weight loss drug.

The case for Pfizer Berobenatide has another advantage: It could be administered monthly. So, even with slightly lower efficacy than weekly anti-obesity medicines, it may attract a large patient population. Further, the medicine's safety and tolerability profile appears strong. Pfizer is planning to run various phase 3 studies for this candidate across weight management and obesity-related comorbidities, including such potential indications as obstructive sleep apnea and knee osteoarthritis. This is clearly a highly promising product, and it seems the market has yet to factor its potential into Pfizer's share price.

Today's Change

(

2.14

%) $

0.56

Current Price

$

26.76

The stock has basically moved sideways since November, when Pfizer acquired Metsera, the biotech company that originally developed berobenatide. It's also worth noting that Pfizer has plenty of other attractive candidates, especially in oncology. Also, even though its financial results haven't been strong, some of the company's products should perform well over the medium term. The list includes Padcev, a cancer medicine. Then there is Pfizer's strong dividend program. The company regularly increases its payouts and currently offers a juicy forward yield of 6.7%. All of those are great reasons to consider the stock.

Beware of these risks However, there are also significant risks to consider. There is, of course, the possibility that berobenatide will not perform as well as expected in phase 3 studies that test investigational drugs in broader, more representative patient populations using more rigorous endpoints. Even beyond that, we should expect many other pharmaceutical leaders to make headway in this field over the next couple of years.

For instance, Amgen (AMGN +1.50%) is also working on a weight loss candidate that could be administered monthly (or less frequently). As more weight loss drugs enter the market, it will become harder for newer medicines to earn approval (regulators will have higher standards), and it may put downward pressure on the prices of these drugs, making them less commercially viable. None of that means Pfizer's berobenatide won't be successful, but it's important to consider this before deciding to buy the company's shares.

Similar risks apply to Pfizer's efforts in oncology and other fields. That's all before we account for the company's upcoming patent cliffs, including that of Eliquis -- one of its best-selling drugs -- by the end of the decade. Can Pfizer overcome these potential challenges? My view is that it is well-positioned to do so, given the breadth of its pipeline across weight management, oncology, and other areas, which gives it multiple opportunities to hit the mark.

Within five years, we could be looking at a transformed lineup of approved drugs that will help replace the company's weakening coronavirus business and the patent cliffs it will soon experience. The stock appears attractive to investors willing to be patient and stay put despite the challenges Pfizer faces.

HomeEarnings AnalysisHealthcare 

SummaryPfizer shares edged higher after Q2 earnings, shrugging off criticism over the discontinuation of two obesity drug candidates, MET-224o and PF-07976016.PFE highlighted Metsera's rapid progress and plans to strategically deploy its remaining $6 billion-$7 billion toward bolt-on opportunities in oncology, IMIDs, and obesity.In Q2, sales of the tafamidis franchise were $1.76 billion, up 10% QoQ.Meanwhile, Abrysvo, an RSV vaccine, generated $208 million in revenue for PFE, up 45.5% from the second quarter of 2025.In this article, I explain why I continue to cover PFE with a 'Strong Buy' rating. seb_ra/iStock via Getty Images

2 days ago, on August 4, Pfizer (PFE) released another strong earnings report.

In Q2, its revenue was $15.03 billion, up 4% quarter-over-quarter and 2.6% YoY.

At the same time, Pfizer's non-GAAP EPS of 77

3.51K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Pfizer on Tuesday reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing an added $1.5 billion in sales from its non-Covid products.

The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares to a previous outlook of $59.5 billion to $62.5 billion. That sales range would still be roughly flat or down slightly compared with 2025 revenue of $62.6 billion.

Pfizer said it cut its full-year revenue expectation for its Covid products – the vaccine and antiviral pill Paxlovid – to $4 billion, down from around $5 billion previously. 

The pharmaceutical giant reiterated its full-year adjusted profit outlook of between $2.80 and $3 per share. 

Here's what the company reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

Earnings per share: 77 cents adjusted vs. 68 cents expectedRevenue: $15.03 billion vs. $14.41 billion expectedPfizer reported revenue of $15.03 billion for the first quarter, up 3% from the same period a year ago. Sales increases for key products, including its blood thinner Eliquis and targeted cancer drug Padcev, helped to counteract struggles in its Covid business.

Eliquis in particular blew past estimates for the quarter, raking in $2.43 billion in sales, up 19%. Analysts were expecting revenue of $2.08 billion, according to StreetAccount.

The company booked a net loss of $248 million, or 4 cents per share, for the period. That compares with net income of $2.91 billion, or 51 cents per share, during the second quarter of 2025. 

Excluding certain items, including restructuring charges and costs associated with intangible assets, Pfizer posted earnings per share of 77 cents for the quarter.

The company also announced the second phase of a multi-year initiative to slash costs, which targets around $1.5 billion in savings through 2029. That phase focuses on what the company called product portfolio enhancements, network structure changes and additional operational efficiencies. 

 The first part of that effort is on track to deliver $1.5 billion in savings by the end of 2027. 

Pfizer announced an additional $1 billion in savings from a separate cost-cutting program, which will be achieved from 2027 to 2029. That adds to the previously announced $5.7 billion in cost savings the company will achieve through the program by the end of the year. 

The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs. Investors are focused on several crucial data releases from Pfizer this year, including data on a combination regimen that includes its GLP-1 injection and an amylin asset.

Posted by Defense World Staff on Aug 3rd, 2026

Pfizer (NYSE:PFE – Get Free Report) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of $0.68 per share and revenue of $14.3994 billion for the quarter. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 10:00 AM ET.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter last year, the firm posted $0.92 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. On average, analysts expect Pfizer to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Price Performance Shares of PFE opened at $25.10 on Monday. Pfizer has a 52-week low of $23.11 and a 52-week high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The business’s 50 day moving average price is $25.04 and its two-hundred day moving average price is $26.16. The firm has a market cap of $143.06 billion, a PE ratio of 19.16 and a beta of 0.34.

Pfizer Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s payout ratio is currently 131.30%.

Wall Street Analysts Forecast Growth Several equities research analysts have weighed in on the stock. UBS Group reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. BMO Capital Markets reduced their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. JPMorgan Chase & Co. decreased their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Finally, Guggenheim lowered their target price on Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.50.

View Our Latest Stock Report on Pfizer

Key Stories Impacting Pfizer Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Positive Phase 3 vitiligo data: Pfizer reported that oral LITFULO significantly improved skin repigmentation in two late-stage trials for nonsegmental vitiligo. The results support planned regulatory filings and could create a new growth opportunity for the company. Reuters LITFULO vitiligo trial article Positive Sentiment: Updated COVID vaccine approved in Europe: The European Commission authorized Pfizer and BioNTech’s XFG-adapted vaccine for the 2026–2027 season across the European Union. The approval enables production and advance supply, although seasonal COVID demand remains difficult to forecast. EU approval article Positive Sentiment: Value appeal and estimates: Investor commentary highlights Pfizer’s roughly 6.8% dividend yield and inexpensive earnings valuation, while Erste Group reportedly raised its FY2027 EPS estimate. These factors may attract income and value-focused investors. Pfizer valuation article Neutral Sentiment: Upcoming earnings focus: Analysts are watching Pfizer’s second-quarter revenue, adjusted earnings, product sales and full-year outlook. The available reports are previews rather than an announcement of actual quarterly results, so earnings remain a near-term catalyst. Pfizer Q2 earnings preview Negative Sentiment: Growth concerns remain: Pfizer’s valuation reflects investor skepticism about post-pandemic revenue, a comparatively modest growth profile and execution risks surrounding its pipeline. Its obesity-drug candidate is promising but still late-stage and faces powerful competition from Eli Lilly and Novo Nordisk, limiting any immediate earnings benefit. Pfizer earnings preview and valuation article Institutional Investors Weigh In On Pfizer Several institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Darwin Wealth Management LLC bought a new stake in shares of Pfizer during the 2nd quarter worth $32,000. IFC & Insurance Marketing Inc. purchased a new position in Pfizer during the 4th quarter valued at about $34,000. Birchwood Financial Partners Inc. purchased a new position in Pfizer during the fourth quarter valued at approximately $38,000. WFA of San Diego LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at $40,000. Finally, Atlas Capital Advisors Inc. bought a new position in Pfizer in the 4th quarter worth about $41,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer (Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Featured Stories Five stocks we like better than Pfizer 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story AbbVie Quietly Solved Its Biggest Problem—Now What? Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade Strategy’s Structural Strength: Hidden in a $8 Billion Illusion

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAutoZone, Inc. $AZO Position Trimmed by First Trust Advisors LP

NEXT HEADLINE »First Trust Advisors LP Sells 41,218 Shares of Royal Caribbean Cruises Ltd. $RCL

Daten zeigten, dass die COVID-19-Impfstoffformulierung für das Jahr 2026-2027, die gegen die XFG-Variante gerichtet ist, eine starke Immunantwort gegen derzeit zirkulierende und neu auftretende Virusvarianten generiertÜber fünf Milliarden Dosen der Pfizer-BioNTech COVID-19-Impfstoffe wurden bereits weltweit zur Verfügung gestelltDer Impfstoff zeigt ein vorteilhaftes Sicherheits- und WirksamkeitsprofilDer Versand wird zeitnah beginnen, um einen schnellen Zugang zu dem Impfstoff der aktuellen Saison zu gewährleisten  NEW YORK und MAINZ, Deutschland, 29. Juli 2026 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass die Europäische Kommission („EK“) die Marktzulassung (Marketing Authorization) für die an die XFG-Variante angepasste COVID-19-Impfstoffformulierung der Unternehmen für die Impfsaison 2026-2027 erteilt hat. Die Zulassung gilt für die aktive Immunisierung zur Vorbeugung von COVID-19, verursacht durch SARS-CoV-2, bei Personen ab 6 Monaten. Die Anpassung basiert auf der Empfehlung der Notfall-Taskforce (Emergency Task Force, „ETF“) der Europäischen Arzneimittel-Agentur (European Medicines Agency, „EMA“), die vorschlägt, COVID-19-Impfstoffe für die Impfsaison 2026-2027 so anzupassen, dass sie gegen die XFG-Variante der JN.1-Linie gerichtet sind. Die Notfall-Taskforce erklärte: „Die Datenlage weist darauf hin, dass eine Anpassung an XFG den bestmöglichen Schutz gegen COVID-19 bieten sollte.“1

Die Marktzulassung ist in allen 27 Mitgliedsstaaten der Europäischen Union („EU“) sowie in Island, Liechtenstein und Norwegen gültig. Pfizer und BioNTech haben bereits auf eigenes Risiko mit der Herstellung des an XFG angepassten monovalenten COVID-19-Impfstoffs begonnen, um die Verfügbarkeit vor Beginn der bevorstehenden Erkältungssaison sicherzustellen, in der die Nachfrage nach COVID-19-Impfungen voraussichtlich steigen wird. Die EU-Mitgliedstaaten sowie Norwegen werden entweder im Rahmen des Vertrags mit der EK oder gemäß den jeweiligen nationalen Mechanismen der einzelnen Staaten beliefert.

Die Genehmigung der EK folgt auf die Empfehlung des Ausschusses für Humanarzneimittel (Committee for Medicinal Products for Human Use, „CHMP“) der EMA vom 23. Juli 2026, die auf der Gesamtheit der bisherigen von Pfizer und BioNTech vorgelegten Daten basiert. Die vorgelegten Daten beinhalten klinische und nicht-klinische Ergebnisse und Daten aus der praktischen Anwendung, die die Sicherheit und Wirksamkeit der COVID-19-Impfstoffe von Pfizer und BioNTech belegen, sowie Daten zur Herstellung/Qualität und nicht-klinische Daten, die zeigten, dass der an XFG angepasste monovalente COVID-19-Impfstoff starke Immunantworten gegen derzeit zirkulierende SARS-CoV-2-Linien generiert, darunter XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1 und andere derzeit zirkulierende Linien.2

Die Unternehmen haben zudem Daten zum aktualisierten COVID-19-Impfstoff bei Zulassungsbehörden weltweit eingereicht. Pfizer und BioNTech beobachten weiterhin die Entwicklung der Epidemiologie von COVID-19, um auf die globalen Bedürfnisse im Bereich der öffentlichen Gesundheit vorbereitet zu sein.

Die COVID-19-Impfstoffe von Pfizer und BioNTech basieren auf BioNTechs unternehmenseigener mRNA-Technologie und wurden von beiden Unternehmen gemeinsam entwickelt. BioNTech ist Inhaber der Marktzulassung für die Impfstoffe in den Vereinigten Staaten, der Europäischen Union, dem Vereinigten Königreich, und anderen Ländern, sowie Inhaber von Notfallzulassungen und weiteren Zulassungen in anderen Ländern.

EU-ZUSAMMENFASSUNG DER PRODUKTCHARAKTERISTIKA

Hier finden Sie eine vollständige Übersicht der Produktcharakteristika für den Pfizer-BioNTech COVID-19-Impfstoff.

Wichtige Sicherheitsinformationen

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung.

COMIRNATY® XFG 30 Mikrogramm/Dosis Injektionsdispersion in einer Fertigspritze (Glas) (ab 12 Jahren): Wirkstoff: COVID-19-mRNA-Impfstoff. Zusammensetzung: Eine Fertigspritze enthält 1 Dosis von 0,3 ml mit jeweils 30 Mikrogramm für XFG kodierender mRNA (eingebettet in Lipid-Nanopartikel). COMIRNATY® XFG 10 Mikrogramm/Dosis Injektionsdispersion (Säuglinge und Kinder von 6 Monaten–11 Jahren): Wirkstoff: COVID-19-mRNA-Impfstoff. Zusammensetzung: Eine Durchstechflasche enthält 1 Dosis von 0,3 ml mit jeweils 10 Mikrogramm für XFG kodierender mRNA (eingebettet in Lipid-Nanopartikel). COMIRNATY® LP.8.1 30 Mikrogramm/Dosis Injektionsdispersion (gefrorene Durchstechflaschen) (ab 12 Jahre): Wirkstoff: COVID-19-mRNA-Impfstoff. Zusammensetzung: Eine Durchstechflasche enthält 6 Dosen von 0,3 ml mit jeweils 30 Mikrogramm für LP.8.1 kodierender mRNA (eingebettet in Lipid-Nanopartikel). Sonstige Bestandteile (in allen oben genannten COMIRNATY® Impfstoffen): ((4-Hydroxybutyl)azandiyl)bis(hexan-6,1-diyl)bis(2-hexyldecanoat) (ALC-0315), 2-[(Polyethylenglykol)-2000]-N,N-ditetradecylacetamid (ALC-0159), Colfoscerilstearat (DSPC), Cholesterol, Trometamol, Trometamolhydrochlorid, Saccharose, Wasser für Injektionszwecke. Anwendungsgebiete: Aktive Immunisierung zur Vorbeugung von COVID-19 durch SARS-CoV-2 bei Säuglingen und Kindern im Alter von 6 Monaten bis 11 Jahren (COMIRNATY® XFG 10 Mikrogramm in 0,3 ml), bzw. bei Personen ab 12 Jahren (COMIRNATY® XFG 30 Mikrogramm in 0,3 ml bzw. COMIRNATY® LP.8.1 30 Mikrogramm in 0,3 ml). Gegenanzeigen: Allergie gegen einen der Bestandteile des Arzneimittels. Nebenwirkungen: Sehr häufig: Schmerzen/Schwellung an der Injektionsstelle; Schmerzempfindlichkeit an der Injektionsstelle (Kinder von 6 Monaten bis 11 Jahren), Ermüdung; Kopfschmerzen; Muskelschmerzen; Gelenkschmerzen; Schüttelfrost; Fieber; Durchfall, Reizbarkeit & Schläfrigkeit (6 Monate bis unter 2 Jahre). Häufig: Übelkeit; Erbrechen (‚sehr häufig‘ bei Schwangeren ab 18 Jahren und bei immungeschwächten Personen im Alter von 2 bis 18 Jahren); Rötung an der Injektionsstelle (‚sehr häufig‘ bei Kindern von 6 Monaten bis 11 Jahren und bei immungeschwächten Personen ab 2 Jahren); vergrößerte Lymphknoten (häufiger beobachtet nach der Auffrischungsdosis). Gelegentlich: Unwohlsein; Schwächegefühl oder Energiemangel/Schläfrigkeit; Armschmerzen; Schlaflosigkeit; Jucken an der Injektionsstelle; allergische Reaktionen wie Ausschlag (‚häufig‘ bei Kindern von 6 Monaten bis unter 2 Jahren) oder Juckreiz; verminderter Appetit (‚sehr häufig‘ bei Kindern von 6 Monaten bis unter 2 Jahren); Schwindelgefühl; starkes Schwitzen; nächtliche Schweißausbrüche. Selten: vorübergehendes, einseitiges Herabhängen des Gesichtes; allergische Reaktionen wie Nesselsucht oder Schwellung des Gesichts. Sehr selten: Entzündung des Herzmuskels (Myokarditis) oder Entzündung des Herzbeutels (Perikarditis), die zu Atemnot, Herzklopfen oder Thoraxschmerzen führen können. Häufigkeit nicht bekannt: schwere allergische Reaktionen; ausgedehnte Schwellung der geimpften Gliedmaße; Anschwellen des Gesichts (ein geschwollenes Gesicht kann bei Patienten auftreten, denen in der Vergangenheit dermatologische Filler im Gesichtsbereich injiziert wurden); eine Hautreaktion, die rote Flecken oder Stellen auf der Haut verursacht, die wie ein Ziel oder eine Zielscheibenmitte mit einer dunkelroten Mitte aussehen können, das von hellroten Ringen umgeben ist (Erythema multiforme); ungewöhnliches Gefühl in der Haut, wie Prickeln oder Kribbeln (Parästhesie); vermindertes Gefühl oder verminderte Empfindlichkeit, insbesondere der Haut (Hypoästhesie); starke Menstruationsblutungen (die meisten Fälle schienen nicht schwerwiegend und vorübergehend zu sein). Verschreibungspflichtig. Stand der Informationen: Juli 2026. BioNTech Manufacturing GmbH, An der Goldgrube 12, 55131 Mainz. Weitere Informationen, Warnhinweise und Vorsichtsmaßnahmen sind der Fachinformation zu entnehmen. www.comirnatyglobal.com.

Das schwarze gleichseitige Dreieck ▼ bedeutet, dass ein zusätzliches Monitoring erforderlich ist, um etwaige Nebenwirkungen zu erfassen. Dies ermöglicht eine schnelle Identifizierung von neuen Sicherheitsinformationen. Einzelpersonen können helfen, indem sie alle Nebenwirkungen, die sie möglicherweise bekommen, melden. Nebenwirkungen können an EudraVigilance oder direkt an BioNTech per E-Mail an [email protected], Telefon +49 6131 9084 0 oder über die Webseite http://www.biontech.de/ gemeldet werden.

Über Pfizer: Breakthroughs That Change Patients’ Lives
Bei Pfizer setzen wir die Wissenschaft und unsere globalen Ressourcen ein, um den Menschen Therapien anzubieten, die ihr Leben verlängern und deutlich verbessern. Wir wollen den Standard für Qualität, Sicherheit und Nutzen bei der Entdeckung, Entwicklung und Herstellung innovativer Medikamente und Impfstoffe setzen. Jeden Tag arbeiten Pfizer-Mitarbeiter weltweit daran, das Wohlbefinden, die Prävention, Behandlungen und Heilung von schwerwiegenden Erkrankungen voranzutreiben. Als eines der weltweit führenden innovativen biopharmazeutischen Unternehmen sehen wir es als unsere Verantwortung, mit Gesundheitsversorgern, Regierungen und lokalen Gemeinschaften zusammenzuarbeiten, um den Zugang zu einer zuverlässigen und erschwinglichen Gesundheitsversorgung auf der ganzen Welt zu unterstützen. Seit mehr als 175 Jahren arbeiten wir daran, etwas für all jene zu bewirken, die auf uns zählen. Wir veröffentlichen regelmäßig Informationen auf unserer Website unter www.Pfizer.com, die für Investoren wichtig sein könnten. Mehr Informationen über Pfizer finden Sie unter www.Pfizer.com, auf X unter @Pfizer und @Pfizer News, LinkedIn, YouTube und auf Facebook unter Facebook.com/Pfizer.

Offenlegungshinweis von Pfizer
Die in dieser Pressemitteilung enthaltenen Informationen entsprechen dem Stand vom 29. Juli 2026. Pfizer übernimmt keine Verpflichtung, die in dieser Mitteilung enthaltenen zukunftsgerichteten Aussagen aufgrund neuer Informationen oder zukünftiger Ereignisse oder Entwicklungen zu aktualisieren.

Diese Pressemitteilung enthält bestimmte in die Zukunft gerichtete Aussagen bezüglich des Pfizer-BioNTech COVID-19-Impfstoffs, einschließlich seiner potenziellen Vorteile, der Herstellung und Versorgung, der Erwartungen hinsichtlich der Nachfrage nach COVID-19-Impfungen sowie einer Genehmigung durch die Europäische Kommission zur Aktualisierung der Marktzulassung für den Pfizer-BioNTech COVID-19-Impfstoff, um die XFG-Variante der JN.1-Linie für die Saison 2026–2027 zu adressieren, welche erhebliche Risiken und Ungewissheiten beinhalten, die dazu führen können, dass die tatsächlichen Ergebnisse wesentlich von den in solchen Aussagen zum Ausdruck gebrachten oder implizierten Ergebnissen abweichen. Zu den Risiken und Ungewissheiten gehören unter anderem: Ungewissheiten bezüglich des kommerziellen Erfolgs des Pfizer-BioNTech COVID-19-Impfstoffs; Ungewissheiten, die mit Forschung und Entwicklung verbunden sind, einschließlich der Fähigkeit, erwartete klinische Endpunkte, Zeitpunkte für den Beginn und/oder den Abschluss klinischer Studien, Zeitpunkte für die Einreichung von Zulassungsanträgen bei den Behörden, Zeitpunkte für die behördliche Zulassung und/oder die Zeitpunkte für die Markteinführung einzuhalten, sowie die Möglichkeit ungünstiger neuer klinischer Daten und weiterer Analysen bestehender klinischer Daten; das Risiko, dass klinische Studiendaten unterschiedlichen Interpretationen und Bewertungen durch Zulassungsbehörden unterliegen; die Frage, ob die Zulassungsbehörden mit dem Design und den Ergebnissen unserer klinischen Studien zufrieden sein werden; ob und wann Anträge bei Zulassungsbehörden in bestimmten Rechtsordnungen für den Pfizer-BioNTech COVID-19-Impfstoff für eine potenzielle Indikation, einschließlich der COVID-19-Impfstoffformulierung für 2026-2027, eingereicht werden können; ob und wann solche Anträge für den Pfizer-BioNTech COVID-19-Impfstoff, die möglicherweise anhängig sind oder eingereicht werden, von den Zulassungsbehörden genehmigt werden, was von unzähligen Faktoren abhängt, darunter die Beurteilung, ob die Vorteile des Produkts die bekannten Risiken überwiegen sowie der Bestimmung der Wirksamkeit des Produkts und, falls genehmigt, ob der Pfizer-BioNTech COVID-19-Impfstoff kommerziell erfolgreich sein wird; Entscheidungen von Zulassungsbehörden, die sich auf die Kennzeichnung, Herstellungsverfahren, Sicherheit und/oder andere Faktoren auswirken, die die Verfügbarkeit oder das kommerzielle Potenzial des Pfizer-BioNTech COVID-19-Impfstoffs beeinflussen können; Risiken und Ungewissheiten im Zusammenhang mit möglichen Änderungen der Impfstoff- oder sonstigen Gesundheitspolitik in der EU, den Vereinigten Staaten von Amerika und anderen Ländern; das Risiko, dass die Nachfrage nach bestimmten Produkten zurückgeht, nicht länger besteht oder nicht den Erwartungen entsprechen könnte, was zu niedrigeren Einnahmen oder einem Überschuss an Lagerbeständen und/oder im Vertriebskanal oder anderen unvorhergesehenen Aufwendungen führen könnte; Ungewissheiten in Bezug auf Empfehlungen und Abdeckung sowie die Akzeptanz von Impfstoffen, Auffrischungsimpfungen, Behandlungen oder Kombinationen davon in der Bevölkerung; Risiken in Bezug auf unsere Fähigkeit, unsere Umsatzprognosen für den Pfizer-BioNTech COVID-19-Impfstoff oder potenzielle zukünftige COVID-19-Impfstoffe präzise antizipieren zu können oder zu erreichen; Risiken und Ungewissheiten im Zusammenhang mit erlassenen oder künftigen Durchführungsverordnungen (Executive Orders) oder anderen neuen oder geänderten Gesetzen oder Vorschriften; Unsicherheiten hinsichtlich der Auswirkungen von COVID-19 auf das Geschäft, den Betrieb und die Finanzergebnisse von Pfizer sowie die wettbewerbliche Entwicklungen.

Weitere Ausführungen zu Risiken und Ungewissheiten finden Sie im Jahresbericht des am 31. Dezember 2025 endenden Geschäftsjahres von Pfizer im sog. „Form 10-K“ sowie in weiteren Berichten im sog. „Form 10-Q“, einschließlich der Abschnitte „Risk Factors“ und „Forward-Looking Information and Factors That May Affect Future Results”, sowie in den zugehörigen weiteren Berichten im sog. „Form 8-K“, welche bei der U.S. Securities and Exchange Commission eingereicht wurden und unter www.sec.gov und www.Pfizer.com abrufbar sind.

Über BioNTech
BioNTech ist ein globales innovatives Biopharma-Unternehmen, das bei der Entwicklung von Therapien gegen Krebs und andere schwere Erkrankungen Pionierarbeit leistet. In der Onkologie möchte BioNTech die Behandlungsmöglichkeiten für Menschen mit Krebs nachhaltig verbessern. Das Unternehmen hat sich zum Ziel gesetzt, innovative Arzneimittel mit tumorübergreifendem oder synergistischem Potenzial zu entwickeln, um Krebs in all seinen Facetten und entlang des gesamten Krankheitsverlaufs – von den frühen bis zu den fortgeschrittenen Krankheitsstadien – zu adressieren. BioNTechs wachsendes Portfolio an onkologischen Produktkandidaten in der späten klinischen Entwicklung umfasst innovative Immunmodulatoren, Antikörper-Wirkstoff-Konjugate und mRNA-Krebsimmuntherapien. BioNTech arbeitet Seite an Seite mit weltweit renommierten und spezialisierten Kollaborationspartnern, darunter Bristol Myers Squibb, Duality Biologics, Genentech (ein Unternehmen der Roche Gruppe), Genmab, MediLink, OncoC4 und Pfizer.

Weitere Information finden Sie unter: www.BioNTech.de.

Zukunftsgerichtete Aussagen von BioNTech
Diese Pressemitteilung enthält bestimmte in die Zukunft gerichtete Aussagen von BioNTech im Rahmen des angepassten Private Securities Litigation Reform Act von 1995, einschließlich, aber nicht begrenzt auf ausdrückliche oder implizite Aussagen bezogen auf: BioNTechs Bemühungen, COVID-19 zu bekämpfen; die Kollaboration zwischen BioNTech und Pfizer; behördliche Anträge und behördliche Genehmigungen oder Zulassungen, einschließlich einer Genehmigung der Europäischen Kommission zur Aktualisierung der Marktzulassung für den COVID-19-Impfstoff von Pfizer-BioNTech, um die XFG-Variante der JN.1-Linie für die Saison 2026-2027 abzudecken; Erwartungen hinsichtlich Herstellung, Vertrieb und Versorgung; qualitative Bewertungen verfügbarer Daten und Erwartungen möglicher Vorteile, einschließlich der Immunantwort des angepassten Impfstoffs auf mehrere SARS-CoV-2-Linien, einschließlich der XFG-Variante der JN.1-Linie sowie andere zirkulierende Sublinien; den Annahmen hinsichtlich zu erwartender Anpassungen in der COVID-19-Impfstoffnachfrage, einschließlich Veränderungen des Umfelds für Bestellungen; und der erwarteten behördlichen Empfehlungen zur Anpassung von Impfstoffen an neue Varianten oder Sublinien. In manchen Fällen können die zukunftsgerichteten Aussagen durch Verwendung von Begriffen wie „wird“, „kann“, „sollte“, „erwartet“, „beabsichtigt“, „plant“, „zielt ab“, “antizipiert”, „schätzt“, „glaubt“, „prognostiziert“, „potenziell“, „setzt fort“ oder die negative Form dieser Begriffe oder einer anderen vergleichbaren Terminologie identifiziert werden, allerdings müssen nicht alle zukunftsgerichteten Aussagen diese Wörter enthalten.

Die zukunftsgerichteten Aussagen in dieser Pressemitteilung basieren auf den aktuellen Erwartungen und Einschätzungen von BioNTech hinsichtlich zukünftiger Ereignisse, und sind weder Versprechen noch Garantien und sollten nicht als solche angesehen werden, da sie einer Reihe von bekannten und unbekannten Risiken, Unsicherheiten und anderen Faktoren unterliegen, von denen viele außerhalb der Kontrolle von BioNTech liegen und die dazu führen könnten, dass die tatsächlichen Ergebnisse wesentlich von denen abweichen, die in diesen zukunftsgerichteten Aussagen ausdrücklich oder implizit zum Ausdruck gebracht werden. Diese Risiken und Ungewissheiten beinhalten, sind aber nicht beschränkt auf: die Unwägbarkeiten, die mit Forschung und Entwicklung verbunden sind, einschließlich der Fähigkeit, die erwarteten klinischen Endpunkte, die Termine für Beginn und/oder Abschluss klinischer Studien, die Termine für die Einreichung von Zulassungen bei den Behörden, die Termine für die behördliche Zulassung und/oder die Termine für die Markteinführung zu erreichen, sowie die Risiken im Zusammenhang mit präklinischen und klinischen Daten, einschließlich der in dieser Pressemitteilung veröffentlichen Daten, und einschließlich der Möglichkeit ungünstiger neuer präklinischer, klinischer oder Sicherheitsdaten und weitere Analysen bereits existierender präklinischer, klinischer oder Sicherheitsdaten; die Art der klinischen Daten, die einer ständigen Überprüfung durch Peer-Review, einer behördlichen Prüfung und einer Marktinterpretation unterliegen; BioNTechs Preis- und Kostenübernahmeverhandlungen mit staatlichen Behörden, privaten Krankenversicherungen und anderen Drittparteien; die künftige kommerzielle Nachfrage und der medizinische Bedarf an Erst- oder jährlichen Auffrischungsdosen mit einem COVID-19-Impfstoff; die Auswirkungen von Zöllen und Eskalationen in der Handelspolitik; die Verfügbarkeit von Rohmaterial zur Herstellung von Impfstoffen; die Formulierung unseres Impfstoffs, dem Dosierungsschema und den damit verbundenen Anforderungen an Lagerung, Vertrieb und Verabreichung, einschließlich der Risiken im Zusammenhang mit der Lagerung und Handhabung nach Lieferung; der Wettbewerb durch andere COVID-19-Impfstoffe oder bezogen auf BioNTechs weitere Produktkandidaten, einschließlich solcher mit anderen Wirkmechanismen und anderen Herstellungs- und Vertriebsbedingungen, basierend unter anderem auf Wirksamkeit, Kosten, Lager- und Lieferbedingungen, die Breite der zugelassenen Anwendung, Nebenwirkungsprofil und Beständigkeit der Immunantwort; die Fähigkeit, Empfehlungen von beratenden oder technischen Impfstoffausschüssen und anderen Gesundheitsbehörden zu erhalten und die Ungewissheit hinsichtlich der kommerziellen Auswirkungen solcher Empfehlungen; den Zeitpunkt und BioNTechs Fähigkeit, behördliche Zulassungen für ihre Produktkandidaten zu erhalten und aufrechtzuerhalten; die Fähigkeit von BioNTechs COVID-19-Impfstoffen, COVID-19 zu verhindern, das von aufkommenden Virusvarianten verursacht wird; BioNTechs Fähigkeit, Forschungsmöglichkeiten zu erkennen und Prüfpräparate zu identifizieren und zu entwickeln; die Fähigkeit und Bereitschaft von BioNTechs Kooperationspartnern, die Forschungs- und Entwicklungsaktivitäten in Bezug auf BioNTechs Produktkandidaten und Prüfpräparate fortzusetzen; die Auswirkungen von COVID-19 auf Entwicklungsprogramme, Lieferketten, Kooperationspartner und die finanzielle Leistungsfähigkeit von BioNTech; unvorhergesehene Sicherheitsbelange und potenzielle Ansprüche, die angeblich durch den Einsatz von BioNTechs COVID-19-Impfstoff sowie anderer von BioNTech entwickelter oder hergestellter Produkte und Produktkandidaten auftreten; die Fähigkeit BioNTechs und ihrer Kollaborationspartner, BioNTechs COVID-19-Impfstoff zu kommerzialisieren und zu vermarkten und, falls sie zugelassen werden, BioNTechs Produktkandidaten; BioNTechs Fähigkeit, ihre Entwicklung und verbundenen Ausgaben zu steuern; regulatorische Entwicklungen in den USA und anderen Ländern; die Fähigkeit, BioNTechs Produktionskapazitäten effektiv zu skalieren und ihre Produkte und Produktkandidaten herzustellen; Risiken in Bezug auf das globale Finanzsystem und die Märkte; und andere Faktoren, die BioNTech derzeit nicht bekannt sind.

Den Leserinnen und Lesern wird empfohlen, die Risiken und Unsicherheiten unter „Risk Factors“ in BioNTechs Bericht (Form 6-K) für das am 31. März 2026 endende Quartal und in den darauffolgend bei der U.S. Securities and Exchange Commission (SEC) eingereichten Dokumenten zu lesen. Sie sind auf der Website der SEC unter www.sec.gov verfügbar. Diese zukunftsgerichteten Aussagen gelten nur zum Zeitpunkt der Veröffentlichung dieser Pressemitteilung. Außerhalb rechtlicher Verpflichtungen übernimmt BioNTech keinerlei Verpflichtung, solche in die Zukunft gerichteten Aussagen nach dem Datum dieser Pressemitteilung zu aktualisieren, um sie an die tatsächlichen Ergebnisse oder Änderungen der Erwartungen anzupassen.

Hinweis: Dies ist eine Übersetzung der englischsprachigen Pressemitteilung. Im Falle von Abweichungen zwischen der deutschen und der englischen Version hat ausschließlich die englische Fassung Gültigkeit.

KONTAKTE

Pfizer:
Medienanfragen
+1 (212) 733-1226
[email protected]

Investoranfragen
+1 (212) 733-4848
[email protected]

BioNTech:
Medienanfragen
Jasmina Alatovic
[email protected]

Investoranfragen
Dr. Douglas Maffei
[email protected]

Fußnoten:
1 ETF. ETF empfiehlt Aktualisierung der COVID-19-Impfstoffe, um XFG-Variante abzudecken. Aktualisiert am 29. Mai 2026. Abgerufen am 25. Juni 2026. https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-xfg-variant
2 Vaccines and Related Biological Products Advisory Committee. Meeting-Präsentation - COVID-19-Impfstoffformulierung für 2026-2027: Unterstützende Daten von Pfizer/BioNTech. 28. Mai 2026. Abgerufen am 25. Juni 2026. https://www.fda.gov/media/192765/download

Posted by Defense World Staff on Jul 27th, 2026

Gabelli Funds LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 508,600 shares of the biopharmaceutical company’s stock after selling 67,900 shares during the period. Gabelli Funds LLC’s holdings in Pfizer were worth $14,281,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Vermillion Wealth Management Inc. raised its position in shares of Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 382 shares during the period. Triad Wealth Partners LLC boosted its holdings in Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 386 shares during the last quarter. Eagle Capital Management LLC grew its position in Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after acquiring an additional 390 shares during the period. ETF Store Inc. grew its position in Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after acquiring an additional 396 shares during the period. Finally, Delta Financial Advisors LLC increased its stake in Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after acquiring an additional 398 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades A number of equities analysts have recently commented on the company. Guggenheim cut their price objective on Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Monday, July 13th. UBS Group reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Citigroup increased their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a report on Tuesday, June 9th. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.50.

Get Our Latest Stock Analysis on Pfizer

Pfizer News Summary Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer announced that PF-08057418 cleared a Phase 1 safety milestone, which helps reinforce confidence in the company’s research pipeline and early-stage development prospects. Article: Pfizer’s PF-08057418 Clears Phase 1 Safety Milestone, Offering a Quiet Boost to Pipeline Confidence Positive Sentiment: Pfizer is advancing PF-08653945 into an early-stage obesity trial, giving investors another potential growth driver in a large and competitive therapeutic market. Article: Pfizer Advances New Obesity Shot With Early Stage Trial of PF-08653945 Positive Sentiment: The FDA granted Priority Review to Pfizer’s Talzenna plus Xtandi regimen for metastatic prostate cancer, which improves the odds of a faster regulatory decision and supports oncology revenue upside if approved. Article: FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer Neutral Sentiment: Unusual call option activity suggests traders are positioning for a move in Pfizer shares, but it does not by itself confirm a fundamental change in the company’s outlook. Neutral Sentiment: Recent commentary on Pfizer’s dividend yield and oncology valuation highlights that investors are still weighing income appeal against execution and growth concerns. Negative Sentiment: Expanded patent litigation tied to Pfizer’s mRNA vaccine business remains a potential overhang, adding legal and operational uncertainty that could pressure sentiment if the dispute escalates. Article: Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside Pfizer Trading Down 0.1% NYSE:PFE opened at $24.52 on Monday. The business’s 50-day moving average is $25.11 and its two-hundred day moving average is $26.17. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The firm has a market capitalization of $139.78 billion, a PE ratio of 18.72 and a beta of 0.35.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the previous year, the firm posted $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Company Profile (Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Further Reading Five stocks we like better than Pfizer RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? These 4 Earnings Reports Expose the Market’s Growing Economic Divide Broadcom May Be the Biggest Winner From Alphabet’s Earnings Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECompound Planning Inc. Takes Position in LyondellBasell Industries N.V. $LYB

NEXT HEADLINE »12,363 Shares in Occidental Petroleum Corporation $OXY Bought by Caxton Associates LLP

The Pfizer logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab

CompaniesJuly 22 (Reuters) - Pfizer (PFE.N), opens new tab said on Wednesday the U.S. ​Food and Drug Administration has ‌granted priority review to its application seeking expanded approval for its prostate ​cancer treatment combination.

The company ​sought expanded approval to use ⁠a combination of two approved ​drugs branded as Talzenna and ​Xtandi in men with metastatic castration-sensitive prostate cancer, whose tumors have ​acquired gene changes known ​as HRR mutations.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

Talzenna and Xtandi are already ‌approved ⁠in the United States for men whose prostate cancer has spread to other parts ​of ​the body ⁠and stopped responding to hormone therapy.

For the ​combination drug, Pfizer said ​the ⁠FDA had set a target decision date in the ⁠last ​quarter of 2026.

Reporting ​by Padmanabhan Ananthan in Bengaluru; Editing by ​Shailesh Kuber and Pooja Desai

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Shares of Pfizer (PFE 0.22%) have fallen more than 50% from their late 2021 highs. That massive drawdown has pushed the dividend yield up to a historically high 6.9%. To put that yield into perspective, the S&P 500 index (^GSPC 1.01%) has a yield of roughly 1.1%, and the average pharmaceutical stock's yield is around 1.5%. As a dividend stock, Pfizer looks historically cheap and relatively cheap. Here's what's going on and why you might want to add this drug maker to your shortlist.

Pfizer has some problems to deal with Companies don't end up with outsize yields for no reason. Pfizer has several major patent expirations coming up. When a blockbuster drug loses patent protection, generic competition typically enters and revenues decline. This is why drug companies are always on the lookout for new drugs.

Image source: Getty Images.

On the new drug front, Pfizer hasn't been seeing the success Wall Street would like to see. Notably, it had to drop a GLP-1 weight-loss drug it was developing in early 2025. That was a public black eye, since it put the company well behind competitors.

There are very good reasons why investors are worried about Pfizer. And, notably, the dividend payout ratio is above 130%. There's also legitimate concern about the dividend's safety.

Things don't always line up in the business world There are definitely things for dividend investors to worry about with Pfizer, and conservative types may want to avoid it. However, there's really nothing out of the ordinary going on with the company. Patent expiration dates and new drug development don't always align the way a company would like. But Pfizer has a long and successful history in the drug sector, so it seems highly likely it will navigate this transition period.

Notably, after its GLP-1 mishap, Pfizer quickly announced the acquisition of a company with a more promising weight-loss drug candidate. It has other notable drugs in its pipeline as well.

Today's Change

(

-0.22

%) $

-0.06

Current Price

$

25.09

On the dividend front, the company's cash flows still cover the payment. Since dividends are paid out of cash flows, Pfizer has more wiggle room than it may seem to support the dividend (including using cash on its balance sheet and taking on additional debt). Management has also been very clear that protecting the dividend is a key priority.

Worth a risk for those willing to invest in out-of-favor stocks Risk-averse investors probably won't like Pfizer. But given the company's strong history, the moves it is making to address the totally normal headwinds it faces, and its stated commitment to the dividend, more aggressive dividend investors may find this cheap income stock compelling enough to put on their shortlists.

A high-yielding dividend may sound great for investors, but it can be a double-edged sword: when it's too high, investors start to worry about its safety. That's a big part of the reason why Pfizer (PFE 0.90%), whose 7.1% yield is well above the S&P 500 average of just 1.1%, isn't able to draw in investors; many are worried the dividend is due for a cut.

Not only is Pfizer's dividend far above average, but it is now also the highest yield in the entire S&P 500. Is this a warning sign for investors that the dividend may be cut in the near future, or could Pfizer prove to be an underrated income stock to buy right now?

Image source: Getty Images.

Pfizer's yield has been volatile in recent years A high yield can be concerning, but that alone doesn't make it risky. Similarly, just because a yield is low doesn't mean it's sustainable, either. The yield can fluctuate significantly because it is tied to the share price. When a stock is rising, its yield falls because it costs more to secure the same level of dividend income. And when it falls, as has been the case with Pfizer's stock in recent years, the yield can rise significantly.

PFE Dividend Yield data by YCharts

If Pfizer posts strong earnings numbers in its upcoming quarterly results, issues promising guidance, or there's positive news around one of its drugs, its share price could take off, and just like that, the yield could come down.

There is, however, some risk with the dividend because Pfizer's earnings haven't been all that strong in recent quarters. During the first three months of the year, the company's diluted per-share profit was $0.47, not much higher than its quarterly dividend rate -- $0.43. There's not much of a buffer there, and investors may also be concerned about its long-term future, as the pharma company deals with patent cliffs and navigates a challenging course ahead, which could see its sales (and profits) drop in the future.

Today's Change

(

-0.90

%) $

-0.22

Current Price

$

24.26

Is Pfizer's stock worth buying? Pfizer's dividend may look shaky, but the good news is the company's earnings aren't in bad shape, and it's in the midst of restructuring and cutting costs, which should give it more breathing room in the future. It has also acquired companies that could unlock more growth opportunities down the road.

While this may not be the type of stock investors can simply buy and forget, Pfizer may be a good option for income investors willing to monitor it closely. As of now, the dividend still looks safe, and this could be an underrated option to consider, especially given its low valuation, as the stock trades at just eight times its estimated future earnings, based on analyst expectations.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Jeff J Mitchell / Getty Images News via Getty Images

Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it. On the July 7 episode of CNBC’s Mad Money, a caller from Orland Park, Illinois pitched Pfizer as an income-and-value setup, and Cramer conceded the case looked tempting. He landed on a reluctant pass anyway, telling the caller, “It kills me to say that a stock that yields 7% that used to have a lot of growth is going to have growth again, but I can’t come up with where the growth is. I just can’t. I’m sorry.”

The Caller and the Setup After a friendly exchange about Cramer’s 2:47 AM wake-up habit and a shout-out to a staffer named Sean, the Orland Park caller framed the question plainly: “I’m looking at a pharmaceutical company. You’ve had the CEO on your show several times over the past few years. Pays a high dividend. Down near the 52-week low. What do you think about Pfizer, Jim?” It is the kind of pitch that usually gets a warmer response from a host who has hosted CEO Albert Bourla repeatedly.

Cramer’s Reasoning on Pfizer Pfizer (NYSE:PFE | PFE Price Prediction) drew a diagnosis rather than an endorsement. Cramer told the caller, “Okay, they do have earnings growth problems. They haven’t been able to make the Seagen acquisition work the way it should. The dividend is safe at 7%.” The Seagen deal, closed in December 2023 for roughly $43 billion, was supposed to seed Pfizer’s post-COVID oncology franchise. Padcev, one of the assets that came over, did grow 39% operationally in Q1 2026, but that has not been enough to offset a 59% drop in Comirnaty and a 63% operational decline in Paxlovid.

The headline numbers still show a company that beats and guides steadily. Pfizer posted Q1 2026 revenue of $14.45 billion against a $13.80 billion estimate, adjusted EPS of $0.75 (a fifth consecutive beat), and reaffirmed FY2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00, per the company’s 8-K filing. Net income of $2.687 billion was down 9.44% year over year, and operating income fell 31.44%. That is the growth gap Cramer is pointing at.

The Core Tension: Safe Yield, No Growth Cramer’s stance boils down to a simple test that a safe payout alone does not clear. Pfizer’s quarterly dividend of $0.43 was raised from $0.42 beginning with the January 2026 payment, extending a long streak of modest increases. FY2025 dividends paid totaled $9.8 billion, and management has signaled no buybacks in 2026 despite a $3.3 billion remaining authorization. Cash is going to the payout and to deals like the ~$7.0 billion Metsera acquisition in obesity/GLP-1 and a $1.35 billion charge to in-license a PD-1 x VEGF bispecific from 3SBio. Those bets could re-seed the pipeline. They have not yet moved the earnings needle in a way that satisfies Cramer.

The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.

What the Market Says The market seems to agree, at least for now. Pfizer closed at $24.05 on July 8, down 6.13% over the past month and roughly flat year to date. The 52-week range runs from $21.97 to $28.28, and the trailing yield sits at 7.25%. Analyst consensus target is $29.00, with 16 Hold ratings dominating the board. Forward P/E of 8x tells you the market is pricing in the patent cliff around Eliquis and Vyndaqel, IRA Medicare Part D redesign pressure, and Most-Favored-Nation drug pricing risk.

For readers weighing this against other high-yield names, our ongoing Paycheck Portfolio coverage tracks how income investors are handling yield traps versus durable payers in 2026.

The Bottom Line Cramer’s take is Cramer’s take. Income investors who care most about a covered 7% payout may reasonably read the same facts and reach a different conclusion, especially with the stock sitting closer to the low end of its 52-week range. Growth investors hunting a catalyst will hear Cramer clearly. This is reporting on his opinion, and readers should treat it as such. Do your own research before acting.

If You'd Bought Amazon When the Motley Fool Said To…In September 2002, Stock Advisor told subscribers to buy Amazon. In December 2004, Netflix. In April 2005, Nvidia. The newsletter still publishes two new stock picks every month — and over 23 years, has more than quadrupled the S&P 500. Here's how to get this month's picks:

- Join Stock Advisor for one year, with a 30-day money-back guarantee

- Get this month's two new picks — plus the Top 10 Rankings and the full historical pick list

- Read the analysis, decide for yourself, and trade through your own brokerage

Five years from now, you'll probably wish you'd bought this month's picks. Don't miss them.

Contact [email protected] for any questions or corrections.

Analysts Rajesh Kumar and Dylan Whitfield downgraded to Hold from Buy and lowered their target forecast to $28 from $32, citing increased uncertainty around key pipeline assets and recent executive leadership changes.

The original bullish thesis centered on Pfizer’s increased R&D focus, a dividend yield of roughly 6%, and management’s goal of delivering high single-digit revenue growth between 2028 and 2032.

However, HSBC analysts now believe those growth expectations are unlikely to be validated in the near term.

Oncology Pipeline Delay Weighs On Growth OutlookA key factor behind the downgrade was a reduction in the probability of success for sigvotatug vedotin (SV) to 40% following its Phase 3 setback in non-small cell lung cancer (NSCLC).

The analysts also raised the stock’s beta to 0.85 from 0.78, contributing to the lower price target.

According to the note, Pfizer’s long-term growth outlook depends heavily on the success of SV, atirmociclib, a VEGF-bispecific oncology program, and, to a lesser extent, its obesity portfolio.

However, analysts said meaningful catalysts for these programs are expected closer to 2027 rather than in the second half of 2026, leaving investors with few near-term events that could resolve the ongoing growth debate.

In the meantime, analysts expect the effects of MFN pricing, IRA-related changes, and loss-of-exclusivity pressures to become increasingly visible.

Management Changes Add Another Layer Of UncertaintyThe report also highlighted recent executive leadership changes as another reason for caution.

With a new chief financial officer and chief strategy officer joining the leadership team under the current CEO, analysts believe investors may wait for greater clarity on the company’s approach to capital allocation and dividend discipline.

While analysts said Pfizer’s valuation appears attractive relative to its medium-term earnings potential, they cautioned that the stock could remain inexpensive unless the company delivers successful pipeline outcomes.

They also warned that the NSCLC setback for sigvotatug vedotin increases uncertainty around future catalysts and could negatively affect investor perception of management’s capital allocation if impairments related to Seagen’s intangible assets emerge.

PFE Stock Price Activity: Pfizer shares were down 2.06% at $23.82 at the time of publication on Monday, according to Benzinga Pro data.

Photo: Molly Woodward / Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Pfizer's (PFE +2.62%) shares have lost more than 50% of their value since late 2021 due to poor financial results. The company has tried to bounce back. Notably, it has expanded its pipeline through acquisitions, the most expensive one of which was its $43 billion buyout of Seagen, a cancer-focused drugmaker, in 2023. However, recent developments may suggest to some that Pfizer's efforts to turn things around are not going to work, and the stock may continue moving south.

Image source: The Motley Fool.

A clinical trial flop and a leadership shake-up One of the promising candidates Pfizer got access to through its acquisition of Seagen was sigvotatug vedotin, an investigational medicine for non-small cell lung cancer (NSCLC), one of the leading causes of cancer death in the world. This is a large market that could help Pfizer generate billions of dollars annually, provided it can gain a foothold in it with this therapy. Unfortunately, that now seems unlikely to happen.

Pfizer recently reported that in a phase 3 clinical trial in previously treated NSCLC patients, sigvotatug vedotin failed to show a statistically significant improvement in overall survival, a key endpoint in cancer clinical studies. In the trial, the medicine was pitted against docetaxel, a chemotherapy medication. These results make it unlikely that sigvotatug vedotin will make significant headway in this narrow indication.

Further, there was more negative news for Pfizer recently. On June 18, the pharmaceutical giant announced that its CFO, Dave Denton, would leave the company on Aug. 15. The market is sometimes wary of leadership changes, especially for a company that has been struggling as much as Pfizer has in recent years. It's also worth noting that the drugmaker will face even more challenges ahead. Pfizer's anticoagulant, Eliquis, one of its best-selling drugs, will lose patent exclusivity by the end of the decade. With all that going on, is it time to give up on Pfizer?

Today's Change

(

2.62

%) $

0.62

Current Price

$

24.29

Focus on the long-term It's a bit premature to definitively say that Pfizer's blockbuster acquisition of Seagen was a waste of money. After all, the company is already benefiting from some of the products the buyout added to its portfolio. For instance, Padcev, a medicine for bladder cancer, is currently an important growth driver for Pfizer. In the first quarter, sales from this therapy totaled $591 million, up 39% year over year. There are also other clinical trial candidates that Pfizer inherited from Seagen that could make significant headway in the next few years.

Elsewhere, Pfizer has other attractive pipeline products that may also help it rebound. The company's work in the weight-loss market finally got a boost -- also thanks to an acquisition -- after several internally developed products went nowhere. Pfizer's GLP-1, MET-097i, showed strong results in phase 2 studies and could eventually become an important medicine in this category. The drugmaker boasts other candidates in areas such as immunology, vaccines, and more.

And some of its newer approvals, such as Abrysvo, a respiratory syncytial virus vaccine, are also performing well. Lastly, Pfizer is a solid dividend stock, with a juicy forward yield of 7.3%. All these factors make the stock attractive, and the CFO change shouldn't alter its prospects much. Pfizer may not bounce back immediately, but the stock could eventually do so as it advances through clinical and regulatory milestones over the next five years. That's why its shares are still a buy.

A Pfizer logo is shown at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025. REUTERS/Mike Blake/File Photo Purchase Licensing Rights, opens new tab

SummaryCompaniesNo proof of Pfizer's direct conspiracy to fix prices45 U.S. states, others sued over 80 generic drugsStates unavailable to commentJune 24 (Reuters) - Pfizer (PFE.N), opens new tab has been dismissed as a defendant in ​a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers ‌and executives of fixing generic drug prices.

In a decision on Tuesday, Chief Judge Michael Shea of the federal district court in Connecticut said the states failed to show that Pfizer and its former Greenstone unit ​conspired with rivals between 2010 and 2014 to rig bids and allocate customers for ​six drug products.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

These included generic versions of Eplerenone tablets for high blood ⁠pressure, Latanoprost drops for glaucoma, and four versions of Clindamycin phosphate for acne.

The states alleged ​that Greenstone executives exchanged more than 360 phone calls and text messages with the Swiss drugmaker ​Sandoz (SDZ.S), opens new tab to coordinate anticompetitive activity.

But the judge said no reasonable jury could find that New York-based Pfizer directly conspired to fix prices, knew of collusion by Greenstone when asked to approve price changes, or was ​liable because Greenstone — the authorized generic manufacturer of Pfizer-branded drugs — acted as its agent.

"Greenstone existed ​for the purpose of selling generic drugs for profit in addition to the strategic value that it provided ‌to ⁠its parent company," Shea wrote. "The states’ contention that it existed for the sole purpose of acting on its parent company’s behalf falls short."

LAWSUIT COVERS 80 GENERIC DRUGSThe dismissal came in a lawsuit brought by 45 U.S. states, the District of Columbia and four U.S. territories, accusing 36 defendants ​of conspiring to fix ​prices of 80 generic ⁠drugs, primarily for skin ailments.

Connecticut Attorney General William Tong has led the litigation, and New York Attorney General Letitia James filed papers opposing ​Pfizer's dismissal motion.

Tong's office had no immediate comment on Wednesday. James' ​office declined ⁠to comment.

Pfizer spun off Greenstone in a 2020 transaction that created Viatris (VTRS.O), opens new tab.

In a statement, Pfizer said it was pleased with the dismissal. It also said Greenstone was a "reliable and trusted supplier of affordable ⁠generic ​medicines for decades, and we will continue to vigorously defend ​against these claims."

Shea oversees two other antitrust lawsuits by state attorneys general related to generic drugs. Pfizer is a ​defendant in one of those cases.

Reporting by Jonathan Stempel in New York, Editing by Louise Heavens

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Acquisitions can be a double-edged sword for companies, as they can quickly bolster revenue and growth opportunities but also add costs and inefficiencies. Healthcare giant Pfizer (PFE +1.31%) has been involved in numerous acquisitions in recent years as it has worked to strengthen its prospects; a major risk for the stock has been uncertainty about where its growth will come from, particularly as it faces patent cliffs on key drugs.

One of the largest deals Pfizer made was the $43 billion acquisition of oncology company Seagen in 2023. It was a major acquisition that gave it some promising cancer-fighting medicines. But Pfizer isn't expecting to make significant deals like this in the near future. Here's how it plans to adjust its strategy and what that could mean for investors.

Image source: Getty Images.

Pfizer looks to take a break from acquisitions When a company is aggressively pursuing acquisitions, it can make it difficult to avoid rising costs, as it may incur acquisition-related expenses and become bloated with additional workers and overhead.

On Pfizer's most recent earnings call, CEO Albert Bourla was asked if there would be any more significant acquisitions in the near future. Bourla indicated that nothing's on the horizon and that the healthcare company will instead focus on enhancing its different businesses with artificial intelligence (AI).

"We think that right now, in the next two years, it is the time to execute on AI transformation of these organizations. That requires not the disruption of a mega merger."

Bourla sees tremendous potential with AI to develop new medicines more quickly. Not only could this accelerate the company's long-term growth, but it may also yield greater cost savings and efficiency, leading to stronger financial results.

Today's Change

(

1.31

%) $

0.33

Current Price

$

25.05

Does this news make Pfizer's stock a better buy? Slowing down its acquisition strategy could be an advantageous move for Pfizer, particularly as it works to use AI to improve its processes. If these AI transformations result in stronger earnings and long-term growth prospects, it's what the stock may need to get out of its funk; shares of Pizer are down 35% in the past five years, as even a low valuation hasn't been enough of a reason to entice investors to buy the stock.

The good news, however, is that the company appears to be moving in the right direction, growing its business and looking for ways to enhance its operations with the help of AI. At less than nine times its estimated future earnings (based on analyst expectations), the stock is deeply discounted and offers investors an excellent margin of safety. Plus, it offers a tremendously high dividend yield of around 6.8%. There may be some uncertainty ahead, but overall, Pfizer may be one of the better bargains in the market right now.